MA28563B1 - 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation - Google Patents
1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisationInfo
- Publication number
- MA28563B1 MA28563B1 MA29429A MA29429A MA28563B1 MA 28563 B1 MA28563 B1 MA 28563B1 MA 29429 A MA29429 A MA 29429A MA 29429 A MA29429 A MA 29429A MA 28563 B1 MA28563 B1 MA 28563B1
- Authority
- MA
- Morocco
- Prior art keywords
- oxadiazol
- modulators
- ones
- ppar delta
- ppar
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/24—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D277/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Ophthalmology & Optometry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US55842004P | 2004-04-01 | 2004-04-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA28563B1 true MA28563B1 (fr) | 2007-04-03 |
Family
ID=34972960
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA29429A MA28563B1 (fr) | 2004-04-01 | 2006-10-31 | 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation |
Country Status (15)
Country | Link |
---|---|
US (2) | US7638539B2 (fr) |
EP (1) | EP1781648A2 (fr) |
JP (1) | JP4813461B2 (fr) |
CN (1) | CN1956984B (fr) |
AU (1) | AU2005230838A1 (fr) |
BR (1) | BRPI0508180A (fr) |
CA (1) | CA2561230A1 (fr) |
IL (1) | IL178166A0 (fr) |
MA (1) | MA28563B1 (fr) |
NO (1) | NO20064951L (fr) |
NZ (1) | NZ549823A (fr) |
RU (1) | RU2365589C2 (fr) |
SG (1) | SG151336A1 (fr) |
WO (1) | WO2005097763A2 (fr) |
ZA (1) | ZA200607852B (fr) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2005230838A1 (en) * | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
US8053598B2 (en) | 2004-05-05 | 2011-11-08 | High Point Pharmaceuticals, Llc | Compounds, their preparation and use |
ES2352085T3 (es) | 2004-05-05 | 2011-02-15 | High Point Pharmaceuticals, Llc | Nuevos compuestos, su preparación y uso. |
ES2449618T3 (es) | 2005-06-30 | 2014-03-20 | High Point Pharmaceuticals, Llc | Ácidos fenoxiacéticos como activadores de PPAR-delta |
WO2007039177A2 (fr) | 2005-09-29 | 2007-04-12 | Sanofi-Aventis | Derives de phenyl-1,2,4-oxadiazolone : procedes de preparation et utilisation comme produits pharmaceutiques |
EA015717B1 (ru) | 2005-12-22 | 2011-10-31 | ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи | Феноксиуксусные кислоты в качестве активаторов ppar дельта |
CA2645719A1 (fr) | 2006-03-09 | 2007-09-13 | High Point Pharmaceuticals, Llc | Nouveaux composes, leur preparation et utilisation |
CA2774999A1 (fr) | 2009-09-30 | 2011-04-07 | President And Fellows Of Harvard College | Procedes de modulation de l'autophagie par la modulation de produits geniques renforcant l'autophagie |
BRPI1107312B1 (pt) * | 2011-11-25 | 2021-09-08 | Universidade Federal De Santa Catarina | Composto de acil-hidrazona |
EP3043789B1 (fr) | 2013-09-09 | 2020-07-08 | vTv Therapeutics LLC | Utilisation des agonistes de ppar-delta pour le traitement de l'atrophie musculaire |
KR101715127B1 (ko) * | 2015-10-30 | 2017-03-15 | 한국과학기술연구원 | 시신경 척수염 예방 또는 치료용 피리미딘 카복실레이트 유도체 |
CN114195786B (zh) * | 2020-09-18 | 2023-08-22 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
CN114195777B (zh) * | 2020-09-18 | 2023-06-20 | 凯思凯迪(上海)医药科技有限公司 | 新型fxr小分子激动剂制备及其用途 |
WO2023147309A1 (fr) | 2022-01-25 | 2023-08-03 | Reneo Pharmaceuticals, Inc. | Utilisation d'agonistes ppar-delta dans le traitement d'une maladie |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5103014A (en) * | 1987-09-30 | 1992-04-07 | American Home Products Corporation | Certain 3,3'-[[[(2-phenyl-4-thiazolyl)methoxy]phenyl]methylene]dithiobis-propanoic acid derivatives |
US4895953A (en) * | 1987-09-30 | 1990-01-23 | American Home Products Corporation | 2-Aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US4826990A (en) * | 1987-09-30 | 1989-05-02 | American Home Products Corporation | 2-aryl substituted heterocyclic compounds as antiallergic and antiinflammatory agents |
US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
CA2377246A1 (fr) * | 1999-06-18 | 2000-12-28 | Ranjit C. Desai | Derives d'arylthiazolidinedione et d'aryloxazolidinedione |
GB9914977D0 (en) * | 1999-06-25 | 1999-08-25 | Glaxo Group Ltd | Chemical compounds |
WO2001017994A1 (fr) * | 1999-09-08 | 2001-03-15 | Glaxo Group Limited | Antagonistes ppar oxazole |
JP4145230B2 (ja) * | 2002-11-01 | 2008-09-03 | 武田薬品工業株式会社 | 神経障害の予防・治療剤 |
AU2005230838A1 (en) * | 2004-04-01 | 2005-10-20 | Aventis Pharmaceuticals Inc. | 1,3,4-oxadiazol-2-ones as PPAR delta |
NZ550857A (en) * | 2004-04-01 | 2009-12-24 | Aventis Pharma Inc | 1,3,4-oxadiazol-2-ones as PPAR delta modulators |
-
2005
- 2005-03-30 AU AU2005230838A patent/AU2005230838A1/en not_active Abandoned
- 2005-03-30 NZ NZ549823A patent/NZ549823A/en unknown
- 2005-03-30 BR BRPI0508180-7A patent/BRPI0508180A/pt not_active IP Right Cessation
- 2005-03-30 JP JP2007506541A patent/JP4813461B2/ja not_active Expired - Fee Related
- 2005-03-30 RU RU2006138494/04A patent/RU2365589C2/ru not_active IP Right Cessation
- 2005-03-30 SG SG200902266-6A patent/SG151336A1/en unknown
- 2005-03-30 CA CA002561230A patent/CA2561230A1/fr not_active Abandoned
- 2005-03-30 WO PCT/US2005/010855 patent/WO2005097763A2/fr active Application Filing
- 2005-03-30 CN CN200580017003.5A patent/CN1956984B/zh not_active Expired - Fee Related
- 2005-03-30 EP EP05767047A patent/EP1781648A2/fr not_active Withdrawn
-
2006
- 2006-09-18 IL IL178166A patent/IL178166A0/en unknown
- 2006-09-19 ZA ZA200607852A patent/ZA200607852B/en unknown
- 2006-09-27 US US11/535,764 patent/US7638539B2/en not_active Expired - Fee Related
- 2006-10-30 NO NO20064951A patent/NO20064951L/no not_active Application Discontinuation
- 2006-10-31 MA MA29429A patent/MA28563B1/fr unknown
-
2009
- 2009-07-20 US US12/505,881 patent/US7872032B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CA2561230A1 (fr) | 2005-10-20 |
AU2005230838A1 (en) | 2005-10-20 |
WO2005097763A3 (fr) | 2005-12-15 |
US20070099964A1 (en) | 2007-05-03 |
US20090275621A1 (en) | 2009-11-05 |
ZA200607852B (en) | 2008-07-30 |
US7872032B2 (en) | 2011-01-18 |
WO2005097763A2 (fr) | 2005-10-20 |
US7638539B2 (en) | 2009-12-29 |
NO20064951L (no) | 2006-10-30 |
NZ549823A (en) | 2009-12-24 |
SG151336A1 (en) | 2009-04-30 |
JP2007531764A (ja) | 2007-11-08 |
BRPI0508180A (pt) | 2007-08-07 |
EP1781648A2 (fr) | 2007-05-09 |
CN1956984A (zh) | 2007-05-02 |
JP4813461B2 (ja) | 2011-11-09 |
RU2365589C2 (ru) | 2009-08-27 |
CN1956984B (zh) | 2010-06-09 |
IL178166A0 (en) | 2006-12-31 |
RU2006138494A (ru) | 2008-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA28563B1 (fr) | 1,3,4-oxadiazol-2-ones en tant que modulateurs de ppar delta et leur utilisation | |
IL232313A (en) | Modulators of indoleamine 2,3-dioxigenase and methods of use of the above | |
MA28900B1 (fr) | Composes et compositions en tant que modulateurs ppar | |
ATE540027T1 (de) | Tetrahydroindazol-cannabinoidmodulatoren | |
DE602005011285D1 (de) | Formmasse von polymer | |
ATE542816T1 (de) | Azabicycloä3.1.0ühexanderivate und ihre verwendung als modulatoren des dopamin-d3- rezeptors | |
MA28869B1 (fr) | Phenylaminothiazoles substitues, et leur utilisation | |
ATE497953T1 (de) | Thiazolderivate als modulatoren des cannabinoidrezeptors | |
CL2005002823A1 (es) | Anticuerpos anti-virus respiratorio sincitial, antigenos y usos de los mismos | |
DK1740612T3 (da) | Pdx1 udtrykkende endoderm | |
ATE381334T1 (de) | 2,5-substituiertetetrahydroisochinoline zur verwendung als 5-ht6 modulatoren | |
IS8352A (is) | Ný rópínírólsamsetning | |
DE602004025354D1 (de) | Gabanerge modulatoren | |
DE60305903D1 (de) | Tropanderivative als ccr5-modulatoren | |
DK2447252T3 (da) | Theramuteinmodulatorer | |
DE602006018166D1 (de) | Polyrotaxanhaltige lösung und verwendung davon | |
IS8327A (is) | Módafíníl breyttar losaðar lyfjasamsetningar | |
ATE432701T1 (de) | Indol-6-sulfonamid-derivate, ihre herstellung und ihre verwendung als 5-ht-6 modulatoren | |
BRPI0905990A2 (pt) | "método cosmético, combinação, composição e kits" | |
FI20041220A (fi) | Uusi lakkaasientsyymi ja sen käyttö | |
DE602004010821D1 (de) | Zentrifugationsvorrichtung | |
ATE432698T1 (de) | Indol-7 -sulfonamid-derivate, ihre herstellung und verwendung als 5-ht-6 modulatoren | |
DE602005025498D1 (de) | Optischer fsk-modulator | |
FR2883288B1 (fr) | Polypeptides modifies de la famille des kap et utilisation en cosmetique | |
FR2854797B1 (fr) | Dithiols et leur utilisation pour le renforcement du cheveu |